PE20130810A1 - Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina - Google Patents
Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquininaInfo
- Publication number
- PE20130810A1 PE20130810A1 PE2013000265A PE2013000265A PE20130810A1 PE 20130810 A1 PE20130810 A1 PE 20130810A1 PE 2013000265 A PE2013000265 A PE 2013000265A PE 2013000265 A PE2013000265 A PE 2013000265A PE 20130810 A1 PE20130810 A1 PE 20130810A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- bradiquinin
- tetrahydrofuranil
- disustituted
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DE TETRAHIDROFURANILO DISUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR B1 DE BRADIQUININA DE FORMULA I, DONDE R1 ES UN GRUPO: 3-AMINO-PIRIDINA-5-IL; 5-PIRIMIDINIL ENTRE OTROS; R2 ES H, CL, F; X ES CH, N, ENANTIOMEROS, DIASTEREOISOMEROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {3-[2-FLUORO-4-(4-METOXI-2-TRIFLUOROMETIL-FENILAMINO)-BENCILCARBAMOIL]-TETRAHIDROFURAN-3-IL}-AMIDA DEL ACIDA(S)-6-OXO-1,6-DIHIDRO-PIRIDAZIN-4-CARBOXILICO; (S)-5-AMINO-N-{3-[2-FLUORO-4-(4-METOXI-2-TRIFLUORMETIL-FENILAMINO)-BENCILCARBAMOIL]-TETRAHIDROFURAN-3-IL}-NICOTINAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO FARMACEUTICO. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO AGUDO Y PROFILACTICO DE DOLORES VISCERALES, NEUROPATICOS ENTRE OTROS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10173489 | 2010-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130810A1 true PE20130810A1 (es) | 2013-07-25 |
Family
ID=44510978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000265A PE20130810A1 (es) | 2010-08-20 | 2011-08-19 | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina |
Country Status (36)
Country | Link |
---|---|
US (1) | US8937073B2 (es) |
EP (1) | EP2606042B1 (es) |
JP (1) | JP5727011B2 (es) |
KR (1) | KR101822371B1 (es) |
CN (1) | CN103068817B (es) |
AP (1) | AP2012006630A0 (es) |
AR (1) | AR082507A1 (es) |
AU (1) | AU2011290727B2 (es) |
BR (1) | BR112013003752A2 (es) |
CA (1) | CA2807086A1 (es) |
CL (1) | CL2013000310A1 (es) |
CO (1) | CO6680689A2 (es) |
CY (1) | CY1115933T1 (es) |
DK (1) | DK2606042T3 (es) |
EA (1) | EA022787B1 (es) |
EC (1) | ECSP13012495A (es) |
ES (1) | ES2525296T3 (es) |
GE (1) | GEP20146196B (es) |
HK (1) | HK1178902A1 (es) |
HR (1) | HRP20141172T1 (es) |
IL (1) | IL224039A (es) |
MA (1) | MA34578B1 (es) |
ME (1) | ME01899B (es) |
MX (1) | MX352548B (es) |
MY (1) | MY156233A (es) |
NZ (1) | NZ607435A (es) |
PE (1) | PE20130810A1 (es) |
PL (1) | PL2606042T3 (es) |
PT (1) | PT2606042E (es) |
RS (1) | RS53622B1 (es) |
SG (1) | SG187835A1 (es) |
SI (1) | SI2606042T1 (es) |
TW (1) | TWI548632B (es) |
UA (1) | UA108765C2 (es) |
UY (1) | UY33565A (es) |
WO (1) | WO2012022795A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007034620A1 (de) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
CA2697946C (en) | 2007-08-29 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Bradykinin b1-antagonists |
US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
EP3200589A4 (en) | 2014-09-10 | 2018-07-25 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
WO2016183150A1 (en) * | 2015-05-12 | 2016-11-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI259079B (en) * | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
EP1476419B1 (en) * | 2002-02-08 | 2006-02-01 | Merck & Co., Inc. | N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
KR20050033660A (ko) * | 2002-08-29 | 2005-04-12 | 머크 앤드 캄파니 인코포레이티드 | N-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체 |
CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n-(联芳基甲基)氨基环丙烷甲酰胺类 |
US7332499B2 (en) | 2003-08-07 | 2008-02-19 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
CA2557858A1 (en) | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
US20060173023A1 (en) | 2005-02-01 | 2006-08-03 | Wood Michael R | 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation |
US7998980B2 (en) * | 2006-09-15 | 2011-08-16 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
EP2025675A1 (de) | 2007-08-14 | 2009-02-18 | Boehringer Ingelheim International GmbH | Arylsulfonamide mit analgetischer Wirkung |
CA2697946C (en) | 2007-08-29 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Bradykinin b1-antagonists |
AR068509A1 (es) * | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
WO2010057899A1 (de) | 2008-11-20 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten |
AU2010217606C1 (en) | 2009-02-26 | 2017-01-19 | Boehringer Ingelheim International Gmbh | Compounds as bradykinin B1 antagonists |
WO2011104203A1 (de) | 2010-02-23 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
WO2010097374A1 (de) | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
EP2606043B1 (de) * | 2010-08-20 | 2014-07-09 | Boehringer Ingelheim International GmbH | Pyridazinderivative als bradykinin b1 rezeptor antagonsiten |
AU2011291614B2 (en) | 2010-08-20 | 2016-05-26 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
-
2011
- 2011-08-12 US US13/208,567 patent/US8937073B2/en active Active
- 2011-08-19 PT PT117486340T patent/PT2606042E/pt unknown
- 2011-08-19 EA EA201201662A patent/EA022787B1/ru not_active IP Right Cessation
- 2011-08-19 NZ NZ607435A patent/NZ607435A/en not_active IP Right Cessation
- 2011-08-19 PL PL11748634T patent/PL2606042T3/pl unknown
- 2011-08-19 AP AP2012006630A patent/AP2012006630A0/xx unknown
- 2011-08-19 RS RS20140551A patent/RS53622B1/en unknown
- 2011-08-19 DK DK11748634.0T patent/DK2606042T3/da active
- 2011-08-19 SG SG2013010764A patent/SG187835A1/en unknown
- 2011-08-19 SI SI201130320T patent/SI2606042T1/sl unknown
- 2011-08-19 MA MA35624A patent/MA34578B1/fr unknown
- 2011-08-19 CA CA2807086A patent/CA2807086A1/en not_active Abandoned
- 2011-08-19 GE GEAP201113031A patent/GEP20146196B/en unknown
- 2011-08-19 KR KR1020137004077A patent/KR101822371B1/ko active IP Right Grant
- 2011-08-19 UY UY0001033565A patent/UY33565A/es not_active Application Discontinuation
- 2011-08-19 BR BR112013003752A patent/BR112013003752A2/pt not_active IP Right Cessation
- 2011-08-19 AR ARP110103036A patent/AR082507A1/es not_active Application Discontinuation
- 2011-08-19 MX MX2013001965A patent/MX352548B/es active IP Right Grant
- 2011-08-19 WO PCT/EP2011/064260 patent/WO2012022795A1/de active Application Filing
- 2011-08-19 AU AU2011290727A patent/AU2011290727B2/en not_active Ceased
- 2011-08-19 TW TW100129857A patent/TWI548632B/zh active
- 2011-08-19 UA UAA201303313A patent/UA108765C2/uk unknown
- 2011-08-19 PE PE2013000265A patent/PE20130810A1/es not_active Application Discontinuation
- 2011-08-19 ES ES11748634.0T patent/ES2525296T3/es active Active
- 2011-08-19 CN CN201180039753.8A patent/CN103068817B/zh not_active Expired - Fee Related
- 2011-08-19 EP EP11748634.0A patent/EP2606042B1/de active Active
- 2011-08-19 ME MEP-2014-118A patent/ME01899B/me unknown
- 2011-08-19 MY MYPI2013000537A patent/MY156233A/en unknown
- 2011-08-19 JP JP2013524457A patent/JP5727011B2/ja active Active
-
2012
- 2012-12-31 IL IL224039A patent/IL224039A/en active IP Right Grant
-
2013
- 2013-01-30 CL CL2013000310A patent/CL2013000310A1/es unknown
- 2013-02-28 CO CO13041062A patent/CO6680689A2/es active IP Right Grant
- 2013-03-15 EC ECSP13012495 patent/ECSP13012495A/es unknown
- 2013-06-04 HK HK13106521.0A patent/HK1178902A1/xx not_active IP Right Cessation
-
2014
- 2014-11-26 CY CY20141100985T patent/CY1115933T1/el unknown
- 2014-12-02 HR HRP20141172AT patent/HRP20141172T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130810A1 (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
NZ590650A (en) | Buprenorphine analogs | |
EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
PE20121180A1 (es) | (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer | |
EA201071339A1 (ru) | Фосфорсодержащие производные в качестве ингибиторов киназы | |
TN2014000398A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists | |
GEP201706728B (en) | Noxious organism control agent | |
EA201500652A1 (ru) | Дифторметилникотиновые инданилкарбоксамиды | |
EA201490579A1 (ru) | Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез | |
MX348451B (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12. | |
EA201390422A1 (ru) | Бупренорфиновые аналоги | |
CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
JO2939B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
PE20142359A1 (es) | Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
ECSP11011151A (es) | Compuestos purina | |
IL199972A (en) | Tricyclic compounds and their use as modulators of glucocorticoid receptor | |
EA201290073A1 (ru) | Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ | |
PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
PE20151748A1 (es) | Inhibidores de bace1 | |
GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
UA114529C2 (uk) | Похідні етинілу як модулятори активності рецептора mglur5 | |
CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
MX360330B (es) | Regimen de administracion para nitrocatecoles. | |
PE20140998A1 (es) | Compuestos heterociclicos como inhibidores de syk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |